Hypothesis

Senescent cells secrete a specific IL‑33 isoform (the truncated, secreted form) that acts as a negotiator by steering macrophages toward an anti‑inflammatory, pro‑repair phenotype; with aging or chronic stress the splicing shifts toward the full‑length, nuclear‑retained IL‑33 that amplifies fibroblast activation and fibrosis.

Mechanistic Rationale

IL‑33 undergoes alternative splicing yielding a secreted isoform (ssIL‑33) and a nuclear isoform (nsIL‑33). Senescent fibroblasts in acute wound environments show elevated SRSF3 activity, favoring ssIL‑33 release. This isoform binds ST2 on alternatively activated macrophages, increasing IL‑10 and TGF‑β1 release, which limits myofibroblast expansion and promotes matrix remodeling. In aged or persistently injured tissue, oxidative stress modifies SRSF3 phosphorylation, reducing ssIL‑33 production and increasing nsIL‑33 accumulation. Nuclear IL‑33 then acts as a transcriptional co‑activator for AP‑1 genes in fibroblasts, driving α‑SMA expression and collagen deposition. Thus the same senescent cell population can switch from negotiator to damage amplifier via an IL‑33 isoform toggle.

Experimental Plan

1. Identify isoform balance – Isolate p16+/p21+ senescent fibroblasts from young (3‑mo) and aged (24‑mo) mouse skin after excisional wound. Perform RT‑PCR with isoform‑specific primers and Western blot for ssIL‑33 vs nsIL‑33. Expect higher ssIL‑33/nsIL‑33 ratio in young wounds.
2. Loss‑of‑function – Use a p16‑CreER;Srsf3^fl/fl mouse to delete SRSF3 specifically in senescent cells. Assess wound closure, macrophage flow cytometry (CD206+ vs iNOS+), and hydroxy‑collagen content at day 14.
3. Gain‑of‑function – Transduce senescent fibroblasts with a ssIL‑33‑expressing vector and inject into aged wounds. Measure macrophage polarization and fibrosis.
4. Blockade – Administer an anti‑ST2 antibody to neutralize ssIL‑33 signaling in young wounds; predict delayed repair and increased α‑SMA+ fibroblasts.

Expected Outcomes

If the hypothesis is correct, SRSF3 loss in senescent cells will shift IL‑33 toward the nuclear isoform, impair macrophage‑mediated repair, and exacerbate fibrosis despite unchanged senescent cell burden. Conversely, ssIL‑33 overexpression in aged wounds will restore pro‑repair macrophage signaling and reduce collagen deposition, even when senescent cells persist.

Potential Pitfalls

Compensatory changes in other alarmins (IL‑1α, HMGB1) could mask IL‑33 effects; we will measure these cytokines to control for confounding. Senescent cell heterogeneity may affect isoform expression; single‑cell RNA‑seq of p16+ cells will verify SRSF3 manipulation efficiency.

Falsifiability

A finding that ssIL‑33 levels do not differ between young and aged senescent fibroblasts, or that manipulating SRSF3/ssIL‑33 fails to alter macrophage polarization or fibrosis, would refute the IL‑33 isoform switch as the mechanistic basis for the negotiator‑to‑damage transition.